Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2/3 2Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Ovarian Neoplasms 2Fallopian Tube Neoplasms 1

Interventions

Cisplatin 23Magnetic Resonance Spectroscopy 18Gemcitabine 15Carboplatin 15pembrolizumab 14Specimen Handling 13Paclitaxel 13Bevacizumab 11Radiotherapy 10Nivolumab 10atezolizumab 9Doxorubicin 9Radiation 8Platinum 8Pemetrexed 8Docetaxel 81,2-diaminocyclohexaneplatinum II citrate 8Drug Therapy 7Dexamethasone 7Temozolomide 6Rituximab 6Radiotherapy, Intensity-Modulated 6Prednisone 6Ipilimumab 6Cytarabine 6Cyclophosphamide 6130-nm albumin-bound paclitaxel 6venetoclax 5Surgical Procedures, Operative 5Immunoglobulin G 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × 1-dodecylpyridoxal × 90 days × Clear all
NCT06161025 2026-05-22

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Daiichi Sankyo

Phase 2/3 Recruiting
860 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07109414 2026-03-09

Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)

Novita Pharmaceuticals, Inc.

Phase 2/3 Active not recruiting
380 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡